Technical Analysis for LSTA - Lisata Therapeutics, Inc.

Grade Last Price % Change Price Change
B 3.16 11.66% 0.33
LSTA closed up 11.66 percent on Friday, November 1, 2024, on 5.08 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Earnings Movers Other 0.00%

   Recent Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lisata Therapeutics, Inc. Description

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Disease Emerging Technologies Stem Cell Cell Therapy Regenerative Medicine Chronic Kidney Disease Angina Stem Cell Therapy Cell Therapy Products

Is LSTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.83
52 Week Low 2.05
Average Volume 11,941
200-Day Moving Average 3.04
50-Day Moving Average 2.96
20-Day Moving Average 2.94
10-Day Moving Average 2.91
Average True Range 0.18
RSI (14) 63.50
ADX 23.39
+DI 31.48
-DI 10.90
Chandelier Exit (Long, 3 ATRs) 2.82
Chandelier Exit (Short, 3 ATRs) 3.26
Upper Bollinger Bands 3.10
Lower Bollinger Band 2.78
Percent B (%b) 1.19
BandWidth 10.78
MACD Line -0.01
MACD Signal Line -0.02
MACD Histogram 0.0103
Fundamentals Value
Market Cap 25.72 Million
Num Shares 8.14 Million
EPS -1.11
Price-to-Earnings (P/E) Ratio -2.85
Price-to-Sales 0.00
Price-to-Book 0.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.96
Resistance 3 (R3) 3.93 3.64 3.83
Resistance 2 (R2) 3.64 3.44 3.65 3.78
Resistance 1 (R1) 3.40 3.31 3.52 3.43 3.74
Pivot Point 3.11 3.11 3.17 3.12 3.11
Support 1 (S1) 2.87 2.91 2.99 2.89 2.58
Support 2 (S2) 2.58 2.78 2.59 2.54
Support 3 (S3) 2.34 2.58 2.49
Support 4 (S4) 2.36